Sugi Predict

Sugi Predict / Compounds / SCHEMBL6785254

SCHEMBL6785254

SCHEMBL6785254

Fc1ccc(-c2cccc3c2[C@@H]2CCNCC[C@@H]2N3)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 3/20 0.42
▸ KCNH2 Q12809 2/20 0.36
▸ REN P00797 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ KDM1A O60341 2/20 0.34
▸ MAOB P27338 1/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ CHRM1 P11229 5/20 0.34
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ WNT1 P04628 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ CHRM3 P20309 2/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ BCL9 O00512 1/20 0.32
▸ CTNNB1 P35222 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785250 1.00 CREBBP (0.42) CREBBPKCNH2RENCYP3A4KDM1A
SCHEMBL6785169 0.89 CREBBP (0.36) CREBBPKCNH2RENCYP3A4BRD4
SCHEMBL6787063 0.89 CHRM1 (0.45) CREBBPKCNH2RENCYP3A4BRD4
SCHEMBL7195591 0.89 CREBBP (0.36) CREBBPKCNH2RENCYP3A4BRD4
SCHEMBL6787066 0.89 CHRM1 (0.45) CREBBPKCNH2RENCYP3A4BRD4
SCHEMBL6784662 0.88 ALOX5AP (0.37) CREBBPKCNH2ALOX5APFEN1LMNA
SCHEMBL6784658 0.88 ALOX5AP (0.37) CREBBPKCNH2ALOX5APFEN1LMNA
SCHEMBL6782255 0.86 PLAT (0.39) CHRM1LMNATSHRWNT1CHRM3
SCHEMBL6782257 0.86 PLAT (0.39) CHRM1LMNATSHRWNT1CHRM3
SCHEMBL6785602 0.86 HTR7 (0.40) KCNH2CHRM1LMNATSHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 — — US disclosed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 — — US disclosed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 — — US disclosed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 CREBBP 3464/4885KCNH2 630/4885REN 803/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 CREBBP 3464/4885KCNH2 630/4885REN 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.